Skip Nav Destination
About the Journal
Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to epidemiologic studies. The journal also publishes News and Research Watch sections.Read More About the Journal
Impact Factor
39.397
Featured Articles
Hallmarks of Cancer: New Dimensions
Douglas Hanahan
PD-1 blockade in solid tumors with defects in polymerase epsilon
Benoit Rousseau, et al.
Noted This Week
In the phase I ANTLER trial, Caribou Biosciences’ chimeric antigen receptor (CAR) T-cell therapy, CB-010, demonstrated an overall response rate (ORR) of 100% in all five evaluable patients with relapsed/refractory B-cell non-Hodgkin lymphoma; patients had already received a median of three treatments. In addition, 80% experienced a complete response (CR) lasting up to 6 months; three patients developed grade 3 or 4 adverse events within 28 days of treatment. Caribou says that "CB-010 is the first allogeneic anti-CD19 CAR T-cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to limit premature CAR T-cell exhaustion."
Trending - Altmetric
Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1
Last mentioned on Sunday May 15 2022
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Last mentioned on Saturday May 14 2022
Colorectal Cancer Growth Is Reduced by the Ketone Body β-Hydroxybutyrate
Last mentioned on Saturday May 14 2022
Tumor-derived Lysophosphatidic Acid Blunts Protective Type-I Interferon Responses in Ovarian Cancer
Last mentioned on Sunday May 15 2022
CCL22 Mutations Promote NK-cell Lymphoproliferative Disease
Last mentioned on Saturday May 14 2022
Advertisement